Does co‐treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
Alimentary Pharmacology & Therapeutics2012Vol. 36(11-12), pp. 1040–1048
Citations Over TimeTop 10% of 2012 papers
Abstract
There may be a benefit from adalimumab+immunosuppressive drugs combination therapy during the first semester of initiating adalimumab, with a slight decrease in adalimumab failure and lower need for adalimumab dosage escalation.
Related Papers
- → Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis(2008)377 cited
- → Effectiveness of infliximab after adalimumab failure in Crohn's disease.(2012)32 cited
- Effectiveness of infliximab after adalimumab failure in Crohn＇s disease(2012)
- → Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease(2013)17 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited